Vitamin B3 may help prevent some common skin cancers
the ONA take:
A large study has found that a certain B3 vitamin may reduce the risk of the most common skin cancers. Melanoma was not involved in the study, only the more common basal and squamous cell cancers.
The study, funded by Australia’s National Health and Medical Research Council, included 386 people who had at least two skin cancers in the previous 5 years.
In the double-blind study, the participants took either 500 mg of the B3 vitamin nicotinamide or dummy pills twice a day for 1 year, and were followed for 6 months after they stopped taking the pills. Those taking the vitamin had a 23% lower rate of new cancers.
In addition, the rate of precancers was also reduced, by 11% after 3 months and 20% after 9 months. However, the benefits did not continue once the pills were stopped. Six months after discontinuing the pills, the rate of new skin cancers was similar in both groups.
Nicotinamide is thought to help repair the DNA damage caused by sun exposure. Vitamin use for cancer prevention, however, is controversial, and some studies have even found them to be harmful.
Furthermore, despite the positive results of this study, the researchers stress that vitamin use is not for people who have not yet had one of these cancers and that people should always practice basic sun-sensible behaviors.
A certain B3 vitamin may reduce the risk of the most common skin cancers.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|